Compare DexCom, Inc. (DXCM) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lockheed Martin Corporation — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Lockheed Martin Corporation trades at $509.13 (market cap $117.22B). The key difference: Lockheed Martin Corporation is far larger — about 3.7× DexCom, Inc.'s market cap, and Lockheed Martin Corporation pays a 2.72% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Lockheed Martin Corporation for 86 Days on average.
| DXCM | LMT | |
|---|---|---|
Market Cap | $31.86B | $117.22B |
Volume | 3,607,070 | 1,101,121 |
Sector | Health | Industrials |
52-Week High | $92.34 | $676.70 |
52-Week Low | $54.84 | $439.19 |
Typical Hold Time | 62 Days | 86 Days |
Enterprise Value | $31.32B | $133.96B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Lockheed Martin (LMT) trades at $508.18, up 1.79% with a bearish technical signal despite recent earnings beat. The defense contractor shows strong fundamentals with $75.05B revenue, 8.16% net margin, and robust cash flow of $8.56B from operations. Recent news highlights AI integration and F-35 program developments, while analyst consensus remains bullish with a $635.33 price target representing 25% upside potential.
LMT presents a compelling value opportunity with attractive valuation multiples (P/E 18.73, P/S 1.53) and 23-year dividend growth streak. Key risks include dependency on Pentagon contracts and fixed-price contract volatility. The stock's current discount to analyst targets and defensive positioning in aerospace/defense sector support long-term investment case despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
